Nov 29, 2022 / 02:00PM GMT
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Good morning. Welcome to the 34th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the specialty pharma team, Eric Piper. Our next company, fireside chat is Organon and we're delighted to have Kevin Ali, CEO and Matt Walsh, CFO. Thanks so much for joining us and lots to talk about. So, let's just dive right in if that's okay.
Kevin Ali - Organon & Co. - CEO & Director
Sure.
Questions and Answers:
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research AnalystSo, I like to start off with a couple of high level questions. And the first is, as we move into '23 -- and I know you get this a lot, what are your biggest priorities in terms of BD M&A? More specifically, is the goal to bolster the pipeline or a commercial stage assets or mix of both?
And the reason I started there is, I guess, it's something that you've talked about a lot on in
Trustpilot
